First Type 1 Diabetes Patient Enrolled in Rise Therapeutics’ Latest Clinical Trial
Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, announced it has enrolled its first patient in its R-5280 placebo-controlled, blinded, Phase 1b type 1 diabetes clinical trial.
UF Health Shands Children’s Hospital Nationally Ranked in Four Specialties
University of Florida Health Shands Children’s Hospital’s diabetes and endocrinology program is now ranked among the nation’s top 10 by U.S. News & World Report. It is the highest ranking ever for the program, which is joined in the standings by three other UF Health pediatric medical specialties, according to the 2023-24 Best Children’s Hospital rankings.
UF Doctor Receives Distinguished Award for ‘Groundbreaking’ Work on Type 1 Diabetes
Director of the University of Florida's Diabetes Institute Dr. Mark Atkinson has received a major science award for his groundbreaking research on Type 1 diabetes.
Inspira Awarded $1.98M NIH Grant for Diabetes Therapy
Inspira Therapeutics was awarded a $1.98 million NIH grant to develop its polymeric biomaterial-based tolerogenic treatment for type 1 diabetes.
UF Diabetes Institute Director Receives International Acclaim for Groundbreaking Research
The director of the University of Florida Diabetes Institute has been awarded the 2019 Jacobæus Prize, one of the top international honors... Read More
Genetic Risk for Autoimmunity May Be Linked to Differences in Gut Microbiome
University of Florida researchers, Eric W. Triplett, Ph.D., Desmond A. Schatz, M.D., and Mark A. Atkinson, Ph.D. along with Linköping University researchers... Read More
